SCHEMBL1198772

SCHEMBL1198772

COC(=O)c1sccc1NS(=O)(=O)c1ccccc1F

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.74
SLC10A6 Q3KNW5 1/20 0.71
MAPT P10636 3/20 0.60
LMNA P02545 3/20 0.60
TSHR P16473 2/20 0.60
HPGD P15428 1/20 0.60
PARP14 Q460N5 1/20 0.53
ALDH1A1 P00352 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
GAA P10253 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
PPARG P37231 1/20 0.50
PPARD Q03181 1/20 0.50
PPARA Q07869 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
CCR2 P41597 1/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
PKM P14618 1/20 0.47
MAPK8 P45983 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1200311 0.89 KCNH2 (0.66) KCNH2SLC10A6MAPTLMNATSHR
SCHEMBL12395476 0.86 SLC10A6 (0.69) KCNH2SLC10A6MAPTLMNATSHR
SCHEMBL7531342 0.85 ACLY (0.54) KCNH2SLC10A6LMNATSHRHPGD
SCHEMBL1199270 0.85 KCNH2 (1.00) KCNH2SLC10A6MAPTLMNATSHR
SCHEMBL1200348 0.85 SMN1; SMN2 (0.69) KCNH2SLC10A6MAPTLMNATSHR
SCHEMBL1200198 0.85 SLC10A6 (0.67) KCNH2SLC10A6MAPTLMNATSHR
SCHEMBL1199591 0.84 KCNH2 (0.80) KCNH2SLC10A6MAPTLMNATSHR
SCHEMBL1200118 0.83 KCNH2 (0.79) KCNH2SLC10A6MAPTLMNATSHR
SCHEMBL2749565 0.82 KCNH2 (0.77) KCNH2SLC10A6MAPTLMNATSHR
SCHEMBL2748962 0.81 KCNH2 (0.69) KCNH2SLC10A6MAPTLMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110028469-A1 Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor ANDERSON ERIC C 2011-02-03 US disclosed
US-20110028469-A1 Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor ANDERSON ERIC C 2011-02-03 US disclosed
US-20110028469-A1 Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor ANDERSON ERIC C 2011-02-03 US disclosed
EP-2207772-A1 THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS MODULATORS OF CCR9 RECEPTOR ENCYSIVE PHARMACEUTICALS, INC. (US) 2010-07-21 EP disclosed
WO-2009044311-A1 THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS MODULATORS OF CCR9 RECEPTOR ENCYSIVE PHARMACEUTICALS INC. (US) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028469-A1 Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor CCR9, CCR1, CCR10 KCNH2 4625/4885SLC10A6 2880/4885MAPT 3701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.